Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Arch Iran Med ; 26(8): 439-446, 2023 Aug 01.
Article in English | MEDLINE | ID: mdl-38301106

ABSTRACT

BACKGROUND: miRNAs are non-coding RNAs participating actively in the post-translational regulation of oncogenes, tumor suppressor, and DNA repair genes implicated in colorectal cancer (CRC). This study aims to examine the association of the variants miR-27a (rs895819 A>G), miR-196a2 (rs11614913 T>G) and miR-146a (rs2910164 C>G) in Mexican CRC patients. METHODS: DNA samples from 183 patients and 186 healthy Mexican subjects were analyzed. Variants were identified by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) methodology. Association was calculated by the odds ratio (OR) and adjusted by the Bonferroni test. RESULTS: Patients carrying the G/G genotype of the rs895819 variant in the miR-27a gene showed an increased risk of CRC (19% vs 12%, P=0.013). A similar tendency was noticed for patients younger than 50 years carrying A/G (48% vs 41%, P=0.014). The A/G genotype in TNM stages I+II (55.7% vs 40.8%, P=0.011) and tumor location in the colon (69.5 vs 40.8%, P=0.001) were also increased. For the variant rs11614913 of the miR-196a2 gene, carriers of the C/C genotype showed an increased risk of CRC (32% vs 22%, P=0.009). This genotype was more frequent in TNM stage III+IV (36.8% vs 22.5%, P=0.007) and the tumor had a more recurrent location in the rectum (31.6% vs 22.5%, P=0.013). The rs2910164 variant of the miR-146a gene was found to have no significant risk associations. CONCLUSION: Our results reveal that the rs895819 variant in miR-27a and rs11614913 in miR-196a2 have a substantial impact on the development of CRC.


Subject(s)
Colorectal Neoplasms , MicroRNAs , Humans , MicroRNAs/genetics , Genetic Predisposition to Disease , Polymorphism, Single Nucleotide , Genotype , Colorectal Neoplasms/genetics , Case-Control Studies
2.
Gac Med Mex ; 150(2): 154-64, 2014.
Article in Spanish | MEDLINE | ID: mdl-24603996

ABSTRACT

The aim of this review is to present a genetic and molecular overview of colorectal carcinogenesis (sporadic and hereditary origin) as a multistage process, where there are a number of molecular mechanisms associated with the development of colorectal cancer and genomic instability that allows the accumulation of mutations in proto-oncogenes and tumor suppressor genes, chromosomal instability, and methylation and microsatellite instability, and the involvement of altered expression of microRNAs' prognosis factors.


Subject(s)
Colorectal Neoplasms/genetics , Carcinogenesis/genetics , Chromosomal Instability/genetics , DNA Methylation , Genes, Tumor Suppressor , Humans , MicroRNAs/metabolism , Microsatellite Instability , Mutation , Proto-Oncogenes/genetics
4.
Rev Neurol ; 55(9): 543-8, 2012 Nov 01.
Article in Spanish | MEDLINE | ID: mdl-23111993

ABSTRACT

INTRODUCTION: Various disorders affecting the canonical Wnt/ß-catenin signalling pathway have been related to the activation or inactivation of oncogenes and tumour suppressor genes that give rise to a number of well-defined neoplasias, as well as several genes involved in a growing group of complaints, including Alzheimer's disease (AD) and fragile X syndrome (FXS). AIM: To examine the Wnt/ß-catenin signalling pathway as a possible common biological mechanism involved in the origin and development of neurodegenerative conditions and its relationship with cancer. DEVELOPMENT: We review the most recent biomedical literature dealing with the Wnt/ß-catenin signalling pathway and its participation in the genesis of complaints such as AD and FXS. An analysis is also conducted to determine the role that this metabolic pathway might play in explaining the lowered risk of developing cancer displayed by these patients. CONCLUSIONS: The evidence found suggests that the Wnt/ß-catenin pathway could be regulating a set of genes linked with the control of the cell cycle and apoptosis. This would give rise to a metabolic state in which, in conditions such as AD and FXS, the cells would be more likely to undergo apoptosis than initiate mitosis, which would in turn account for the reduced risk of developing cancer.


Subject(s)
Alzheimer Disease/physiopathology , Fragile X Syndrome/physiopathology , Wnt Proteins/physiology , Wnt Signaling Pathway/physiology , beta Catenin/physiology , Alzheimer Disease/epidemiology , Apoptosis/physiology , Ataxia/epidemiology , Ataxia/physiopathology , Comorbidity , Disease Resistance , Female , Fragile X Syndrome/epidemiology , Humans , Male , Mitosis/physiology , Models, Biological , Neoplasms/epidemiology , Nerve Degeneration/physiopathology , Neurogenesis/physiology , Risk , Tremor/epidemiology , Tremor/physiopathology
5.
Eur J Med Genet ; 55(11): 611-4, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22828468

ABSTRACT

Brachydactyly type C (BDC), a well-recognized autosomal dominant hand malformation, displays brachymesophalangy of the second, third, and fifth fingers, a short first metacarpal, hyperphalangy, and ulnar deviation of the index finger. An "angel-shaped phalanx" is a distinctive radiological sign that can be found in BDC and other skeletal dysplasias, such as angel-shaped phalango-epiphyseal dysplasia (ASPED), an autosomal dominant skeletal abnormality characterized by a typical angel-shaped phalanx, brachydactyly, specific radiological findings, abnormal dentition, hip dysplasia, and delayed bone age. BDC and ASPED result from mutations in the CDMP1 gene. We report here a Mexican patient with BDC and clinical features of ASPED who carries a novel mutation in CDMP1, confirming that BDC and ASPED are part of the CDMP1 mutational spectrum. Based on the large number of clinical features in common, we suggest that both anomalies are part of the same clinical spectrum. Supported by an extensive review of the literature, a possible genotype-phenotype correlation in the mutational spectrum of this gene is proposed.


Subject(s)
Bone Diseases, Developmental/genetics , Brachydactyly/genetics , Growth Differentiation Factor 5/genetics , Bone Diseases, Developmental/diagnosis , Bone Diseases, Developmental/diagnostic imaging , Brachydactyly/diagnosis , Brachydactyly/diagnostic imaging , Child , Epiphyses/diagnostic imaging , Fingers/abnormalities , Frameshift Mutation , Genetic Association Studies , Heterozygote , Humans , Male , Radiography , Sequence Deletion
6.
Cir Cir ; 80(4): 389-98, 2012.
Article in Spanish | MEDLINE | ID: mdl-23374390

ABSTRACT

The Wnt-ß-catenin signalling pathway plays a crucial role in the regulation, differentiation, proliferation and cellular death processes; consequently, alterations in this pathway are involved in numerous abnormalities of development, growth and homeostasis in animal organisms. Wnt proteins include a numerous family of secretion glycoproteins which join to Frizzled receptors and Low Density Lipoprotein Receptor-related Protein, in order to stabilize the critical ß-catenin protein, and to initiate an intricate signaling cascade, which is related to multiple nucleocytoplasmatic processes. Alterations in the canonical Wnt-ß-catenin signaling pathway have been associated with variations in a number of proteins participating in this route, or with activation / inactivation of oncogenes and tumor suppressor genes, which explain different processes of tumorigenesis, in addition to a number of malformations and human diseases. This review describes the relations between the Wnt-ß-catenin signaling pathway with different neoplasic processes, as well as its application in the diagnosis and prognosis of cancer.


Subject(s)
Neoplasms/physiopathology , Wnt Signaling Pathway , Cell Transformation, Neoplastic/genetics , Gene Expression Regulation, Neoplastic , Gene Silencing , Genetic Therapy , Humans , Intracellular Signaling Peptides and Proteins/physiology , Leukemia/genetics , Leukemia/metabolism , Leukemia/physiopathology , Molecular Targeted Therapy , Neoplasm Proteins/physiology , Neoplasms/genetics , Neoplasms/metabolism , Neoplasms/therapy , Wnt Proteins/physiology , beta Catenin/physiology
7.
Rev Invest Clin ; 63(6): 651-8, 2011.
Article in Spanish | MEDLINE | ID: mdl-23650678

ABSTRACT

Lysosomal storage diseases (LSD) are caused by monogenic mutations in genes coding for multiple aberrant proteins involved in the catabolism of complex lipids, glycosaminoglycans, oligosaccharides, or nucleic acids. The pathophysiology of the LSD is due to abnormal accumulation of non-hydrolyzed substrate in the lysosomes, affecting the architecture and function of cells, tissues and organs. Due to their genic and allelic heterogeneity the LSD present a wide clinical spectrum in severity of symptoms, evolution and age of onset. The therapeutic strategy has two goals: 1) Palliative management of symptoms (splenectomy, surgery to improve or restore joints or bones, drugs for CNS symptoms, etc.), and 2) The correction of activity of the mutant protein, the former has two approaches: A) Replacing deficient protein (bone marrow transplantation, hematopoietic stem cells or umbilical cord blood cells; replacement with recombinant enzyme and gene therapy) and B) Activate or enhanced the functionality of the mutant enzyme with therapeutic small molecules. Neither of the known treatments is able to address all aspects of these multisystemic disorders, nor cure the patients. Currently, the combination of corrective therapy (CT) with paliative therapy (PT) is the most promising strategy to solve most of the multisystem manifestations. The multidisciplinary medical care is fundamental for diagnosis, treatment and control of disease. Nanotechnology opens a promising new era in the treatment of LSD. Finally, the LSD that has CT must be included in newborn screening programs in order to implement timely treatment and prevent irreversible damage.


Subject(s)
Lysosomal Storage Diseases/therapy , Aminoglycosides/pharmacology , Aminoglycosides/therapeutic use , Combined Modality Therapy , Disease Management , Enzyme Replacement Therapy , Genetic Therapy , Humans , Infant, Newborn , Lysosomal Storage Diseases/diagnosis , Lysosomal Storage Diseases/diet therapy , Lysosomal Storage Diseases/drug therapy , Lysosomal Storage Diseases/epidemiology , Lysosomal Storage Diseases/genetics , Molecular Chaperones/therapeutic use , Neonatal Screening , Palliative Care , Patient Care Team , Peptide Chain Termination, Translational/drug effects , Protein Folding/drug effects , Recombinant Proteins/therapeutic use , Splenectomy , Stem Cell Transplantation
SELECTION OF CITATIONS
SEARCH DETAIL
...